Fumarylacetoacetate hydrolase (FAH) domain-containing proteins (FAHD) are identified members of the FAH superfamily in eukaryotes. Enzymes of this superfamily generally display multi-functionality, involving mainly hydrolase and decarboxylase mechanisms. This article presents a series of consecutive methods for the expression and purification of FAHD proteins, mainly FAHD protein 1 (FAHD1) orthologues among species (human, mouse, nematodes, plants, etc.). Covered methods are protein expression in E. coli, affinity chromatography, ion exchange chromatography, preparative and analytical gel filtration, crystallization, X-ray diffraction, and photometric assays. Concentrated protein of high levels of purity (>98%) may be employed for crystallization or antibody production. Proteins of similar or lower quality may be employed in enzyme assays or used as antigens in detection systems (Western-Blot, ELISA). In the discussion of this work, the identified enzymatic mechanisms of FAHD1 are outlined to describe its hydrolase and decarboxylase bi-functionality in more detail.
Introduction
The fumarylacetoacetate hydrolase (FAH) 1,2 superfamily of enzymes describes a group of enzymes that share the highly conserved catalytic FAH domain 3, 4, 5, 6, 7, 8, 9, 10 . Despite their common catalytic center, these enzymes are multi-functional, and most are found in prokaryotes, where they are used to break down compounds retrieved from complex carbon sources 3 . Only three members of this family were identified in eukaryotes so far: the name giving FAH 2 , as well as FAH domain-containing protein 1 (FAHD1) 11, 12, 13, 14, 15 and FAH domain-containing protein 2 (FAHD2). Depletion of FAHD1 has been associated with impaired mitochondrial respiration 13, 16 and associated with a reversible Based on defined pores in the silica material, proteins may be separated by their size (in a first approximation corresponding to their molecular mass). Small proteins permeate the porous column material and are retarded, while large proteins migrate faster around the porous particles. Please click here to view a larger version of this figure.
1. Proceed from step 2.5 (i.e., the protein is in Ni-NTA running buffer and filtered by 0.22 µm filter units on ice). 2. Prepare an empty plastic or glass column by washing the empty column and attaching it to a stable retainer. Choose the size of the column depending on the volume of the protein suspension. 3. For each 10 mL of protein suspension, apply 500 µL of Ni-NTA agarose slurry into the column (shake heavily before usage). Apply the slurry slowly and dropwise onto the bottom filter of the column using a pipette. Let the column settle, which takes a few seconds. 4. Fill the column completely with Ni-NTA running buffer, ensuring not to disrupt the agarose resin. Let the buffer run through by gravity. The process may be accelerated up by applying thumb pressure onto the liquid (using a lid or glove and thumb pressure), but take care not to distort the agarose resin. 5. Apply the protein suspension. As before, let the sample run through by gravity. Accelerating this step using thumb pressure is not recommended, as binding of proteins to the column is enhanced if the flow rate is low. Collect the flow-through in a tube (Table of Materials). 6. After the sample has passed through, fill the whole column again with Ni-NTA running buffer. Take care to not disrupt the agarose resin. Let the sample run through by gravity, but in contrast to the previous step, accelerating the process via thumb pressure is recommended, as potential contaminations because of unspecific interactions may be disrupted this way. Collect the washing solution in a tube. Repeat this step. 7. Place a UV-transparent cuvette below the column and apply 1 mL of Ni-NTA elution buffer. Collect the sample without applying any thumb pressure to the resin. 8. Check the optical density (OD) of the sample at 280 nm vs. a blank sample (i.e., Ni-NTA elution buffer). Optimally, the sample displays an OD of greater than 2.5. An OD below 0.5 denotes that no significant amount of protein is in the sample. NOTE: As outlined in the discussion section, salt and imidazole concentrations of the elution buffer may have to be adapted for each FAHD protein individually. 9. Repeat steps 3.1.7 and 3.1.8 until the OD falls below 0.5. Pool all samples with higher OD in a tube on ice. 10. Start again with step 3.1.4, using the flow-through from step 3.1.5 as new input for this repetition of step 3.1.5. Repeat this process until the first sample collected in step 3.1.6 displays an OD below 0.5. NOTE: As outlined in the troubleshooting part of the discussion section, His-tagged proteins may bind insufficiently to the Ni 2+ -resin. In such cases, repetition of this step or alternative methods (e.g., ion exchange chromatography) are required. Take samples of all intermediate fractions for SDS-PAGE analysis. 12. FAHD proteins in Ni-NTA elution buffer will precipitate upon freezing and thawing. Therefore, dialyze the protein against a different buffer (overnight on ice, using 1 µL of DTT per 100 mL of dialysis buffer). Use low-salt buffer based on which type of ion-exchange chromatography should be performed after this step. Use common cellulose tubing with a typical molecular weight cut-off of 14 kDa ( 
Purification of untagged FAHD proteins via hydrophobic interaction chromatography (HIC)
NOTE: Phenyl-groups on the coating surface of a silica gel in a HIC column for FPLC ( Figure 3B ) enable the separation of proteins according to hydrophobic character. The described steps should be performed with an FPLC system equipped with a 5 mL of HIC-phenyl column. Columns may be washed with 1 M NaOH to be reused for different proteins. However, columns once used for one type of FAHD protein should be reused for only this type of protein. Check the pH (7.0); this is buffer A. Buffer B is 250 mL of running buffer. Add 1 mM DTT to both buffers A and B, then keep them on ice. 
Purification of FAHD proteins via ion exchange chromatography
NOTE: Molecules with charged functional groups are bound to a silica particle column for FPLC ( Figure 3C ). This enables the differentiation of proteins according to their ionic character, such as surface charge. The described steps should be performed with an FPLC machine and associated know-how, respectively. The described method is the same for either cationic or anionic exchange chromatography, but the buffers to be used are slightly different.
1. Chose the cationic or anionic exchange chromatography system. This choice is empirical and may vary among FAHD proteins. Optimally, both methods can be used consecutively. 2. Setup the FPLC system and wash the column with 5 CV of 20% EtOH (in H 2 O), followed by 5 CV of H 2 O. Equilibrate the column with 1 CV of low-salt buffer, high-salt buffer, and again low-salt buffer in this sequence. 3. Apply the sample (dialyzed against the correct low salt buffer from step 3.1.11) onto the column. Collect the flow-through. Wash the column for 1 CV with low salt buffer. 4. Setup a gradient elution: 100% high-salt buffer in 30 min at a flow rate of 1 mL/min, or 60 min at a flow rate of 0.5 mL/min. This may be reselected based on an already known FPLC chromatogram, in order to optimize the purification. Collect all peak fractions. NOTE: High-salt conditions may vary among FAHD proteins, as outlined in the discussion section. 5. After the gradient has finished, run with high-salt buffer until no more peaks are detected over the range of 1 CV (collect the fractions). 6. Take samples of all collected fractions and perform SDS-PAGE analysis (12.5% running gel, 4% stacking gel). Freeze the individual samples in liquid nitrogen and store them at -80 °C. 7. After SDS-PAGE analysis is complete, pool the samples containing the FAHD protein and discard the others. Optionally, concentrate the protein using ultra-centrifugation filter units. 8. Apply 1 mL of 25% SDS in 0.5 M NaOH (or other detergents) to clean the column. Wash the column with H 2 O and 20% EtOH (in H 2 O). 9. Optionally, repeat section 5 with the alternate column (cationic or anionic exchange chromatography). The protein obtained from this method is sufficiently pure to perform basic activity assays or can be used in screening assays for crystallography. For advanced applications, proceed with section 6. 1. Start up a microplate reader and equilibrate for 30 min at 25 °C. Setup a program for reading 12 wells (as outlined in Figure 4A ) at 255 nm. It is recommended to use 25 multiple readouts with 5 ms time delay. Setup a cycle to measure 15x every 2 min (30 min total). 2. By default, prepare an enzyme assay buffer (see Table of ) in enzyme assay buffer. 5. According to the pipetting scheme displayed in Figure 4A , prepare the enzyme blank and sample wells: pipet 90 µL of enzyme assay buffer (Table of Materials) into the wells with 5 µL (5 µg) of enzyme solution. 6. According to the pipetting scheme displayed in Figure 4A , prepare the substrate blank and sample wells: pipet 95 µL of enzyme assay buffer into the wells. 7. Right before measuring, apply 5 µL of enzyme assay buffer into the six blank wells. Apply 5 µL of the 20 mM substrate solution to the sample wells. It is recommended to use a multichannel pipette.
Crystallization of FAHD proteins
NOTE: Crystallization of FAHD proteins (human FAHD1 described previously 15 ) may be achieved by the hanging drop vapor diffusion method in a 24 well format ( Figure 6A) . A step-by-step protocol on crystallization of human FAHD1 using this technique is presented below 15 . A more detailed description is provided in the discussion section. . See section 9 for more details. (C) Human FAHD1 crystals and corresponding diffraction patterns (small inserts). The closest lattice spacing is indicated in the inserts as a measure for diffraction quality of the crystals. Lower numbers indicate higher resolution and thus more informative data. See section 9 of the protocol for more details. Please click here to view a larger version of this figure.
1. Ensure that the protein is dialyzed against SEC running buffer. The FAHD1 protein should be available at high concentrations (2-5 mg/mL).
At lower concentrations, the protein may not crystallize due to lack of spontaneous nucleation. 2. Prepare ≥20 mL of the reservoir solution for crystallization. Make three stock solutions, using distilled or deionized water as a solvent: 1 M Na-HEPES (minimum 25 mL, adjusted to pH 7.5), 50% (w/v) polyethylene glycol 4000 (PEG4k) (minimum 65 mL), and 1 M MgCl 2 (10 mL).
3. Setup a grid of 4 x 6 (24 total) different 15 mL tubes. Label them according to corresponding positions on the plate (e.g., row (A, B, C, D) vs. column (1-6) like "A1", "B5", "D6", etc.). Pipette 1 mL of 1 M Na-HEPES into each tube. 4. Pipette 1 mL of 50% (w/v) PEG4k into row A of the tubes, 2 mL into row B, 3 mL into row C, and 4 mL into row D. Pipette 100 µL of 1 M MgCl 2 into column 1 of the tubes, 250 µL into column 2, 500 µL into column 3, 1.0 mL into column 4, 1.5 mL into column 5, and 2.0 mL into column 6. 5. Fill all tubes up to a 10 mL volume with distilled or deionized water, where the scale on the tubes is sufficiently accurate. 6. Take the human FAHD1 protein sample (~5 mg/mL) from the fridge (or from ice) and spin down at maximum speed with a table top centrifuge at 4 °C for at least 10 min. If co-crystallization with oxalate is desired, add oxalate from a stock solution so that the protein sample contains a final oxalate concentration of 2 mM. Apply 1 mM DTT and store on ice. 7. In the meantime, unpack a 24 well crystallization plate, ideally inside a temperature-controlled room at 18 °C. Distribute a thin layer of paraffin oil onto the rim on top of every well of the 24 well plate with the help of a thin glass or plastic rod. Add 800 µL of the prepared crystallization cocktails (A1 to D6) into each corresponding well of the crystallization plate. 8. Place fresh 22 mm coverslips onto a clean surface. Avoid contaminating the cover slips with dirt or dust. If necessary, remove any debris from the cover slip using compressed air or a duster spray. 9. After centrifugation is complete, avoid shaking the protein sample so that the spun-down aggregates and debris at the bottom of the tube do not float up again. In the following steps, pipette from the protein sample just below the surface of the solution in order to avoid stirring up aggregates and deposits from the bottom. 10. For each well (see Figure 6B ) pipette 1 µL of protein solution onto the center of a cover slip and add 1 µL of the respective reservoir cocktail to the protein droplet, avoiding bubbles. Turn the coverslip upside down and place it onto the top of the well so that the oil seals the well with the coverslip air-tight. Repeat until the 24 well plate is completed. 11. Store the plate at 18 °C and observe the drops on a progressive schedule with a proper microscope. Human FAHD1 crystals usually appear overnight (see Figure 6C ).
Representative Results
Starting with a prepared cloning vector and purchased BL21(DE3) pLysS E. coli, the plasmid is inserted into the bacteria via heat-shock or any appropriate alternative method (Figure 1) . After a short period of amplification, the transformed bacteria are plated on LB agar plates, in order to grow overnight. Plates at this point may look different, depending on a variety of potential error sources. Plates may be empty (i.e., no colonies), completely overgrown by bacteria, or something in between, respectively. Two examples of LB agar plates after optimal and nonoptimal transformation are depicted in Figure 7A . Too many bacterial colonies indicate either that too many bacteria were plated (likely) or that the antibiotics in use may be expired (unlikely). Too few bacterial colonies may indicate that either not enough plasmid was used for the transformation (use more next time) or that too much antibiotics were used to select the bacteria. In any case, if colonies are present, they should be fine, as using two selective antibiotics implies a rather insignificant chance of untransformed bacteria to grow. No colonies at all, however, indicates that either the bacteria lost their transformation competence (because of wrong storage or storage over longer periods, repetitive freeze and thaw, etc.), the heat-shock was not successful (no plasmid uptake or bacterial death by too much heat), the cloning vector is corrupted, or by mistake a wrong set of selective antibiotics was used (verify the resistance gene on the plasmid vector).
Some unexpected problems may occur during Ni-NTA purification in step 3.1.10. Of note, a higher OD in the second collected sample than in the first sample indicates a too high volume of the agarose resin (take a note and use less resin in the next experiment). Also, the agarose resin itself leads to an OD signal at 280 nm (i.e., disruption of the agarose resin bed will give artificial signals). In case of doubt, it is advised to use other methods like a Bradford or BSA assay to determine protein concentrations.
In enzymatic assays, there are three critical aspects to be considered. First, assessing the protein concentration is critical to obtain the correct specific activities. The level of purity of the protein is influencing the result and needs to be estimated. In case of tagged protein, the mass of the tag-part has to be computed, and the specific activity has to be correspondingly corrected. For simple assays described in section 7 of the protocol, Ni-NTA purity is sufficient to distinguish between active and inactive substrates, cofactors, etc. In the case of more complex Michaelis-Menten kinetics, all reactant and substrate concentrations must be correctly determined. Especially when using oxaloacetate (which auto-decarboxylates over time) the enzymatic part of the reaction must be corrected for auto-decarboxylation (under the assumption that both reactions occur simultaneously). Initial changes in the optical density signal addressed to keto-enol tautomerization of the substrate must be considered. Third, concentrations and volumes must be adjusted. A reaction with defined concentrations of enzyme and substrate may give different results dependent on the assay volume. If there is too much enzyme per well, adhesion of the liquid may in fact bias the result.
For assessing Michaelis-Menten kinetics it is recommended to perform initial experiments in 100 µL, 200 µL, and 300 µL batches in order to find the optimal combination. Similar aspects apply to the ratio of enzyme-substrate concentrations for kinetic assays. Too much enzyme per substrate or too much substrate per enzyme put the system outside the linear steady-state Michaelis range. Initial experiments are required to optimize these conditions. Exemplary adjustment for human FAHD1 (wild-type) protein are provided in section 8, resulting in kinetic diagrams (as presented in Figure 5B , for example).
For crystallization a droplet of protein solution is pipetted in the center of a coverslip and mixed with a droplet of crystallization cocktail, which is usually composed of a buffer (e.g., Tris-HCl, HEPES) and a precipitant (e.g., polyethylene glycol, ammonium sulfate). A droplet of inhibitor solution for co-crystallization (such as oxalate in this protocol) may optionally be applied. The coverslip is then placed upside down above a well of reservoir containing crystallization cocktail, sealing the well air tight with the help of sealant oil ( Figure 6B) . Ideally, no precipitation occurs within the drop at the beginning of the experiment meaning the protein remains in solution. Since precipitant concentration in the reservoir is higher than in the drop, the drop starts to lose water by evaporation into the atmosphere of the well until equilibrium with the reservoir is reached. The diffusion of water into the reservoir causes a slow volume decrease of the drop which in turn causes an increase of both, protein and precipitant concentration in the drop. If the protein solution reaches the required state of super-saturation and thus meta-stability, spontaneous nucleation followed by crystal growth can occur. Reaching the supersaturated state is a necessary but not sufficient condition for crystallization. Crystallization of proteins needs both, favorable thermodynamic and kinetic conditions, and heavily depends on the unpredictable properties of the protein to be crystallized 22 .
Modifications and Troubleshooting
Expression of protein in E. coli may be inefficient. Varying IPTG concentrations, expression temperature, and amplification time, such as room temperature for several hours or in cold room overnight, may need to be tested for each new protein to find optimal conditions. Precipitation of protein in inclusion bodies is sometimes observed for more hydrophobic FAHD proteins. In such cases, protein expression in other model systems such as insect cells is recommended, as inclusion bodies are less likely to form 26 .
As FAHD proteins are sensitive to salt and cofactor concentrations, as well as pH, purification strategies for different homologues, orthologues, and point mutation variants may differ in individual settings. The purification methods described are developed for the wild-type human and mouse FAHD1 protein. Concentrations of chemicals, such as NaCl and imidazole, as well as pH, may have to be adapted for individual proteins with a different isoelectric point (pI). Also of note, not every His-tagged protein may bind well to a Ni-NTA resin. If protein binding to the Ni-NTA column is inefficient, adapted concentrations of NaCl and imidazole, as well as varying pH conditions in the Ni-NTA running buffer may help to improve the quality of the outcome. If not, skipping the Ni-NTA step and proceeding to the step of ionic exchange chromatography may also lead to a successful purification strategy. If a protein binds to the Ni-NTA column but cannot be eluted from the column, addition of some mM EDTA may help disrupt the Ni 2+ complex.
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The Decarboxylase Activity of FAHD1
Oxaloacetate exists in crystalline state as well as in neutral solution mainly in the Z-enol form 24 . But it was shown that under physiological pHconditions (buffer conditions at pH 7.4) the 2-keto form is the predominant representation of oxaloacetate 25 ( Figure 9A) , and that enolization is not a prerequisite for decarboxylation 27 . Of note, Mg 2+ ions have no influence on the ratio of the oxaloacetate species at a pH of 7.4 or below 28 . Transposition of the oxaloacetate keto form into the catalytic center of FAHD1 (guided by the bound oxalate in the complexed enzyme (PDB: 6FOG 15 )) revealed residue Q109 as a conformational regulator of the bound oxaloacetate 15 . As outlined in another article 15 , hydrogen bonding to the carbamoyl group of Q109 stabilizes an oxaloacetate-conformation resulting from rotation around the C Figure 9C) . Carbon dioxide can be released. The primary product of this process would be resonance stabilized Mg-enolate of pyruvate. It is known from investigations of oxaloacetate-Mg complexes that the enolate forms the most stable complex
The given interpretation suggests pyruvate enol as a distinct intermediate in the catalytic ODx function of FAHD1. At this step in the hypothesized model, experimental data does not provide any further indication as to why the closed lid should open to release the product. It may be deduced, however, that the proposed mechanism looks like an enzyme inhibition by the product: The crystal structure reveals a conserved water molecule held in directional orientation towards the FAHD1 catalytic center by residues H30 and E33 presented in a short helix 15 , which is induced upon ligand binding and lid closure. If the primary enol would stay in an equilibrium with the enolate, the resonance stabilized enolate could be quenched to pyruvate by the water molecule. The resulting hydroxyl would be capable to displace the pyruvate from the Mg-cofactor upon which the lid would open. Finally, the catalytic center would be restored in the mitochondrial environment. In this hypothetic scenario, the cavity water molecule would operate as an acid, respectively.
Hydrolase Activity of FAHD1
Hydrolase activity of an enzyme implicitly requires the intermediate formation of a hydroxyl nucleophile. This mechanism is usually found in combination with acid-base catalytic activity. The transitional state of the reaction has to be prepared via conformational control by critical amino acid side chains in the cavity. In analogy to the discussion of the decarboxylase function, enzyme-bound acylpyruvate in 2-keto form will be put under conformational control by hydrogen-bonding of the 4-carbonyl oxygen to Q109 (Figure 9B, right panel) . The crystal structure of oxalatebound FAHD1 (PDB:6FOG) reveals a conserved water molecule held in directional orientation towards the FAHD1 catalytic center by residues H30 and E33 presented in a short helix 15 . The E33-H30 dyad is competent to deprotonate the directional positioned water and the resulting hydroxyl is in ideal disposition to attack the 4-carbonyl of acylpyruvate presented under conformational control by Q109 15 .
Of note, a similar mechanism has been proposed for FAH 18 . Attack by the hydroxyl nucleophile is expected to result in an oxyanion species, that is stabilized upon orbital controlled C 3 -C 4 bond cleavage ( Figure 9C ). In this model, the C 3 -C 4 bond rotation ( Figure 9C ) happens after the nucleophilic attack by the formed hydroxyl indicated in Figure 9B (i.e., it prepares the acylpyruvate for the bond cleavage). The primary products would be acetic acid and Mg-pyruvate enolate. In this hypothetic scenario, the acetic acid could quench the enol to pyruvate and subsequently assist displacement of the product. Above a pH of 7.5 and in the presence of Mg ions, acylpyruvates exist in an equilibrium between keto-and enol-forms, the latter in slight preference 30 . Most probably both forms are capable to bind to the cofactor of FAHD1 under subsequent lid closure. Processing of enolic acylpyruvate substrates by the enzyme is hampered due to the flat structure of the enol-form. The C Therefore, we propose a catalytic ketonization step to prepare for attack of the hydroxyl nucleophile on the acyl carbonyl. This process of ketonization, however, would require control over proton transpositions by FAHD1 residues, which would attribute an inherent isomerase activity to FAHD1. It is reported that the acidity of Mg-bound enol hydrogen reveals a ten-thousand-fold increase compared to the un-complexed form 28 . A deprotonation of the Mg bound enol-form would be feasible by un-protonated K123. Deprotonation of K123 may be assisted by the carboxylate of D102. A hydrogen bond network formed by residues D102-K47-K123 could operate as the necessary proton relay in the catalytic center of FAHD1 15 . A such-formed intermediate enolate could then be quenched by a E33-H30-H 2 0 triad under ketonization of the substrate 15 . The 2-keto form would come under conformational control of Q109, and the concomitantly formed hydroxyl would attack the acyl carbonyl. The summarized discussion implies a control of FAHD1 about a water molecule for switching between acid and base through interplay of cavity-forming residues.
Future Applications or Directions of the Method
Future applications of the methods described here are numerous. A plethora of prokaryotic members of the FAH superfamily still awaits functional characterization. Even the available information on the catalytic activities of known FAH superfamily members is scarce and, in most cases, based on theoretical assumptions rather than experimental data. Application of the methods described here for prokaryotic FAH superfamily members depends on the specific research interests in bacteriology. On the other hand, the recent demonstration that eukaryotic FAH superfamily members play essential roles in various cellular compartments (e.g., cytosol vs. mitochondria) highlights the need to better characterize these proteins (three of which have been identified so far), in particular because current data suggest that some uncharacterized proteins may carry out different functions in the context of mitochondrial biology, aging research, and cancer research. It is proposed that the full molecular and physiological characterization of these eukaryotic FAH superfamily members may provide important insight into major fields of contemporary research in the biomedical sector. More research on the mechanisms of FAHD1 (and related enzymes) are needed to better understand mechanisms underlying the bi-functionality of FAHD1, which is still not fully clarified. Additional studies with FAHD1 mutants, NMRinvestigations, and structural studies on inhibitor complexes may help resolve the true mechanistic scenarios for which FAHD1 seems to be competent. Furthermore, computer-aided design of enol mimics capable to bind to the Mg-cofactor will eventually lead to potent inhibitors of FAHD1.
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